ACTRN12617000855325终止2 期
Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2: The EMBRACE study
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.Patients, aged 18 years and older, that are either:
- •a) men or women with confirmed evidence of metastatic triple negative breast cancer (TNBC) (ER- PR- HER2- by usual site assessment)
- •b) women with confirmed evidence of relapsed high grade serous ovarian cancer (including fallopian tube cancer or primary peritoneal cancer) or high grade endometrioid ovarian cancer (HGSOC).
- •2.Patients meeting eligibility criteria 1a (TNBC cohort) must have received anthracycline and/or taxane containing chemotherapy.
- •3.Patients meeting eligibility criteria 1b (HGSOC cohort) must have received adjuvant platinum containing chemotherapy.
- •4.Tumour demonstrates genetic or epigenetic evidence of HR deficiency as reported by either by the usual site assessment or on central laboratory testing by the HR deficiency screening.
- •5.Target lesions according to RECIST v1.1. Patients with only non-target lesions are ineligible. Patients with rising CA125 only are ineligible.
- •6.Performance status of ECOG 0 - 1.
- •7.Adequate bone marrow function (e.g. Hb greater than or equal to 100 g/L, platelets greater than or equal to 100 x 109/L, ANC greater than or equal to 1.5 x 109/L), with no blood product transfusions or growth factors received within 28 days.
- •8.Adequate liver function (e.g. serum bilirubin less than or equal to 1.5 x ULN, ALT/AST less than or equal to 2.5 x ULN unless liver metastases are present in which case AST/ALT less than or equal to 5x ULN).
- •9.Adequate renal function (e.g. creatinine clearance greater than or equal to 50 mL/min
- •10.Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments.
- •11.Signed, written informed consent.
排除标准
- •1.Known carriers of pathogenic or likely pathogenic germline BRCA1/2 mutations. This must be tested prior to study entry, either by the usual site assessment or on central laboratory testing by the HR deficiency screening.
- •2.Tumour demonstrates pathogenic or likely pathogenic germline BRCA1 or BRCA2 mutations on central laboratory testing.
- •3.Symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required unless clinically indicated. The patient can receive a stable dose of corticosteroids for brain metastasis, before and during the study, as long as these were started at least 28 days prior to commencing study treatment and provided this is not the only site of measurable disease.
- •4.First relapse with measurable disease on imaging within 6 months following completion of debulking and chemotherapy (HGSOC cohort only). Interval debulking and pre-operative chemotherapy will be allowed.
- •5.Any previous platinum chemotherapy for metastatic/relapsed disease, except:
- •a.TNBC patients where a suitable tumour tissue sample collected following receipt of platinum containing therapy is available. Neoadjuvant platinum containing therapy is also permitted providing screening is undertaken on a post-platinum tumour tissue specimen (e.g. mastectomy or local resection).
- •b.HGSOC patients with somatic or germline mutations in HRD genes other than BRCA1/2 may receive prior lines of non-study treatment and will be eligible after receiving previous treatment for metastatic/relapsed disease.
- •6.Participation in another clinical study with an investigational product within 28 days prior to commencing study treatment.
- •7.Treatment with another anti-cancer treatment within 28 days prior to commencing study treatment.
- •8.Any previous treatment with a PARP inhibitor, including olaparib.
- •9.Known hypersensitivity to any excipients of olaparib.
- •10.Patients who are unable to swallow orally administered medication or have gastrointestinal disorders likely to interfere with absorption of the study medication (e.g. including but not limited to partial bowel obstruction or chronic malabsorption syndrome, Crohn’s disease and ulcerative colitis).
- •11.Blood transfusions within 28 days prior to commencing study treatment. Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable, for timing refer to inclusion criteria no.7)
- •12.Patients with myelodysplastic syndrome/acute myeloid leukaemia. Patients with a peripheral blood smear with features suggestive of MDS/AML are not eligible.
- •13.Uncontrolled seizures.
- •14.Known interstitial lung disease/pneumonitis.
- •15.Receiving the following classes of inhibitors of CYP3A4 (see Section 5 for guidelines and wash out periods).
- •- Azole antifungals
- •- Macrolide antibiotics
- •- Protease inhibitors
- •16.Current toxicities (CTCAE = grade 2) caused by previous cancer therapy (except alopecia or peripheral neuropathy).
- •17.Not recovered from the effects of major surgery, if the surgery was within 14 days prior to starting study treatment.
- •18.Life expectancy of less than 3 months.
- •19.History of another malignancy within 3 years prior to registration. Patients with or who:
- •a) curatively treated earlystage cervical carcinoma or carcinoma in situ,
- •b) non-melanomatous carcinoma of the skin,
- •c) superficial bladder tumours (T1a [Non-invasive tumour], and Tis [Carcinoma in situ]),
研究者
相似试验
进行中（未招募）
1 期
Trial of dostarlimab (TSR-042) for patients with high-risk locally advanced cervical cancer after chemo-radiatioMedDRA version: 21.1Level: LLTClassification code: 10008229Term: Cervical cancer Class: 10029104Cervical cancerCTIS2023-510268-11-00Grupo Espanol De Investigacion En Cancer De Ovario132
进行中（未招募）
1 期
Trial of TSR-042 for patients with high-risk locally advanced cervical cancer after chemo-radiatioCervical cancerEUCTR2018-002155-15-ESGrupo Español de Investigación en Cáncer de Ovario (GEICO)132
进行中（未招募）
不适用
Phase II clinical trial exploring the activity of crizotinib in patients with advanced solid tumors induced by causal alterations of specific receptors (ALK and MET/HGF receptor tyrosine kinases) expressed by cancer sells.ocally advanced and/or metastatic malignant tumor (anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, papillary renal cell carcinoma type 1, alveolar soft part sarcoma, clear cell sarcoma or alveolar rhabdomyosarcoma) deemed incurable by conventional surgery, radiotherapy, systemic therapy or any other meansMedDRA version: 15.1Level: LLTClassification code 10065867Term: Alveolar rhabdomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: PTClassification code 10002227Term: Anaplastic large cell lymphoma T- and null-cell typesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: PTClassification code 10001882Term: Alveolar soft part sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001988-52-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER582
已完成
2 期
Phase II trial on Programmed death-One inhibitor plus RadioThERapy in patients with Metastatic Mucosal MelanomaMetastatic Mucosal MelanomaJPRN-UMIN000030533Kyoto University20
招募中
2 期
Phase II trial on Programmed death-One inhibitor plus RadioThERapy in patients with Metastatic Mucosal MelanomaMelanomaJPRN-jRCT1051200028omura Motoo20